{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:50:20Z","timestamp":1769640620691,"version":"3.49.0"},"reference-count":35,"publisher":"BMJ","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Dis Child Fetal Neonatal Ed"],"published-print":{"date-parts":[[2008,3]]},"abstract":"<jats:sec>\n                  <jats:title>Background:<\/jats:title>\n                  <jats:p>To date there is no firm conclusion as to the efficacy and safety of ibuprofen compared with indometacin for patent ductus arteriosus (PDA) closure in extremely premature infants.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective:<\/jats:title>\n                  <jats:p>To conduct a randomised controlled trial to better address this problem.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>119 infants (gestational age \u2a7d28 weeks) with respiratory distress syndrome and PDA confirmed by echocardiography were randomly assigned to receive either indometacin (0.2 mg\/kg) or ibuprofen (10 mg\/kg), starting at &lt;24 hours of life, followed by half these first doses within 48 hours at 24-hour intervals if indicated by echocardiographic PDA flow pattern.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>The PDA closure rate and the doses of drug (mean (SD)) were similar in both groups: 53\/60 (88.3%) and 1.9 (1.5) mg\/kg in infants given ibuprofen, and 52\/59 (88.1%) and 1.9 (1.7) mg\/kg in infants given indometacin. No significant difference was found in the numbers of infants requiring surgical ligation, and the levels of post-treatment serum creatinine and urea nitrogen between the two groups. Although not significantly different, more infants (9\/59 (15.3%)) treated with indometacin tended to develop oliguria (&lt;1 ml\/kg\/h) than those treated with ibuprofen (4\/60 (6.7%)). There were no significant differences in side effects or complications between the two groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p>Ibuprofen is as effective as indometacin for the early-targeted PDA treatment in extremely premature infants, without increasing the incidence of complications. When the echocardiographic PDA flow pattern was used as a guide for PDA treatment, fewer doses of drugs were needed to achieve acceptable closing rates.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/adc.2007.120584","type":"journal-article","created":{"date-parts":[[2007,9,3]],"date-time":"2007-09-03T20:14:11Z","timestamp":1188850451000},"page":"F94-F99","source":"Crossref","is-referenced-by-count":46,"title":["Comparison of ibuprofen and indometacin for early-targeted treatment of patent ductus arteriosus in extremely premature infants: a randomised controlled trial"],"prefix":"10.1136","volume":"93","author":[{"given":"B-H","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H-C","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H-Y","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H-Y","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H-H","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y-C","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2007,9,3]]},"reference":[{"key":"2025090503454276000_93.2.F94.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197609022951003"},{"key":"2025090503454276000_93.2.F94.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197609022951004"},{"key":"2025090503454276000_93.2.F94.3","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1056\/NEJM198203043060903","article-title":"Prophylactic indomethacin therapy for patent ductus arteriosus in very-low-birth-weight infants.","volume":"306","author":"Mahony","year":"1982","journal-title":"N Engl J Med"},{"key":"2025090503454276000_93.2.F94.4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1542\/peds.68.1.99","article-title":"Indomethacin and its effects on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus.","volume":"68","author":"Betkerur","year":"1981","journal-title":"Pediatrics"},{"key":"2025090503454276000_93.2.F94.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)83391-8"},{"key":"2025090503454276000_93.2.F94.6","doi-asserted-by":"publisher","DOI":"10.1136\/adc.61.3.233"},{"key":"2025090503454276000_93.2.F94.7","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)93030-S"},{"key":"2025090503454276000_93.2.F94.8","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1203\/00006450-199306000-00015","article-title":"Effect of indomethacin on cerebral oxidized cytochrome oxidase in preterm infants.","volume":"33","author":"McCormick","year":"1993","journal-title":"Pediatr Res"},{"key":"2025090503454276000_93.2.F94.9","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1139\/y79-126","article-title":"Age-dependent changes in the response of the lamb ductus arteriosus to oxygen and ibuprofen.","volume":"57","author":"Coceani","year":"1979","journal-title":"Can J Physiol Pharmacol"},{"key":"2025090503454276000_93.2.F94.10","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1152\/jappl.1993.74.4.1672","article-title":"Indomethacin compromises hemodynamics during positive-pressure ventilation, independently of prostanoids.","volume":"74","author":"Malcolm","year":"1993","journal-title":"J Appl Physiol"},{"key":"2025090503454276000_93.2.F94.11","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0022-3565(25)32861-2","article-title":"Differential effects of ibuprofen and indomethacin in the regional circulation of the dog.","volume":"219","author":"Feigen","year":"1981","journal-title":"J Pharmacol Exp Ther"},{"key":"2025090503454276000_93.2.F94.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3468(83)80015-3"},{"key":"2025090503454276000_93.2.F94.13","doi-asserted-by":"publisher","DOI":"10.1159\/000014165"},{"key":"2025090503454276000_93.2.F94.14","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.21.5.777"},{"key":"2025090503454276000_93.2.F94.15","first-page":"336","article-title":"Prevention of postasphyxial increase in lipid peroxides and retinal function deterioration in the newborn pig by inhibition of cyclooxygenase activity and free radical generation.","volume":"33","author":"Chemtob","year":"1993","journal-title":"Pediatr Res"},{"key":"2025090503454276000_93.2.F94.16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(95)91304-1","article-title":"Ibuprofen treatment of patent ductus arteriosus.","volume":"346","author":"Patel","year":"1995","journal-title":"Lancet"},{"key":"2025090503454276000_93.2.F94.17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03530310045031"},{"key":"2025090503454276000_93.2.F94.18","doi-asserted-by":"crossref","first-page":"F179","DOI":"10.1136\/fn.76.3.F179","article-title":"Treatment of patent ductus arteriosus with ibuprofen.","volume":"76","author":"Van Overmeire","year":"1997","journal-title":"Arch Dis Child"},{"key":"2025090503454276000_93.2.F94.19","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-002-0915-y"},{"key":"2025090503454276000_93.2.F94.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(99)70093-4"},{"key":"2025090503454276000_93.2.F94.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(97)70060-X"},{"key":"2025090503454276000_93.2.F94.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200009073431001"},{"key":"2025090503454276000_93.2.F94.23","doi-asserted-by":"crossref","first-page":"F36","DOI":"10.1136\/fn.77.1.F36","article-title":"Echocardiographic assessment of ductus arteriosus shunt flow pattern in premature infants.","volume":"77","author":"Su","year":"1997","journal-title":"Arch Dis Child"},{"key":"2025090503454276000_93.2.F94.24","doi-asserted-by":"crossref","first-page":"F197","DOI":"10.1136\/fn.81.3.F197","article-title":"Echocardiographic flow patterns of patent ductus arteriosus. A guide to indomethacin treatment in premature infants.","volume":"81","author":"Su","year":"1999","journal-title":"Arch Dis Child"},{"key":"2025090503454276000_93.2.F94.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(78)80282-0"},{"key":"2025090503454276000_93.2.F94.26","first-page":"33","article-title":"A survey on the treatment strategy of patent ductus arteriosus in very low birth weight infants.","volume":"39","author":"Su","year":"1998","journal-title":"Acta Paediatr Sin"},{"key":"2025090503454276000_93.2.F94.27","first-page":"CD003481","article-title":"Ibuprofen for the treatment of patent ductus arteriosus in preterm and\/or low birth weight infants.","volume":"4","author":"Ohlsson","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"2025090503454276000_93.2.F94.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.01.047"},{"key":"2025090503454276000_93.2.F94.29","first-page":"CD004213","article-title":"Ibuprofen for the prevention of patent ductus arteriosus in preterm and\/or low birth weight infants.","volume":"1","author":"Shah","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"2025090503454276000_93.2.F94.30","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2001.110528"},{"key":"2025090503454276000_93.2.F94.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17477-1"},{"key":"2025090503454276000_93.2.F94.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17476-X"},{"key":"2025090503454276000_93.2.F94.33","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-199107000-00021"},{"key":"2025090503454276000_93.2.F94.34","first-page":"179","article-title":"Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs.","volume":"15","author":"Smith","year":"1995","journal-title":"Semin Nephrol"},{"key":"2025090503454276000_93.2.F94.35","doi-asserted-by":"crossref","unstructured":"Vane JR Botting RM . Mechanism of action of anti-inflammatory drugs. In: Sinzinger H Samuelsson B Vane JR , eds. Advances in experimental medicine and biology. Vol 433. Recent advances in prostaglandin, thromboxane, and leukotriene research. New York: Plenum Press, 1997:131\u20138.","DOI":"10.1007\/978-1-4899-1810-9_27"}],"container-title":["Archives of Disease in Childhood - Fetal and Neonatal Edition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/adc.2007.120584","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T10:45:51Z","timestamp":1757069151000},"score":1,"resource":{"primary":{"URL":"https:\/\/fn.bmj.com\/lookup\/doi\/10.1136\/adc.2007.120584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,3]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2008,2,22]]},"published-print":{"date-parts":[[2008,3]]}},"alternative-id":["10.1136\/adc.2007.120584"],"URL":"https:\/\/doi.org\/10.1136\/adc.2007.120584","relation":{},"ISSN":["1359-2998","1468-2052"],"issn-type":[{"value":"1359-2998","type":"print"},{"value":"1468-2052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,3]]}}}